The role of biomarker testing in NSCLC

touchMDT for touchONCOLOGY Listen to a medical oncologist and a pathologist discuss the evolving role of biomarker testing in NSCLC in the light of emerging testing methodologies and treatment targets. The multidisciplinary team Medical oncologist: Dr Alexander Drilon, USA  Pathologist: Prof. Keith Kerr, UK This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics,  Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/